PMID: 15228164Jul 2, 2004Paper

Genetics of the variable expression of CYP3A in humans

Therapeutic Drug Monitoring
Leszek Wojnowski

Abstract

CYP3A isozymes participate in the metabolism of 45-60% of currently used drugs and of a variety of other compounds such as steroid hormones, toxins, and carcinogens. The CYP3A expression status is a major determinant of drug efficacy and safety, and it may also affect an individual's predisposition to certain cancers. The inter- and intraindividual expression of CYP3A is variable because of a complex interplay between genetic and environmental factors. Markers predictive of the individual CYP3A activity could improve therapies with CYP3A substrates by personalised dose adjustments, but their development has been slower than for other drug-metabolizing enzymes. Here we summarize the recent progress in genomics and regulation of CYP3A. The recently described markers of the CYP3A5 and CYP3A7 polymorphisms should facilitate the development of isozyme-specific activity markers for the individual CYP3A isozymes, including CYP3A4.

References

Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Jan 11, 1992·Clinical Pharmacology and Therapeutics·C M HuntP S Guzelian
Jul 1, 1988·Biochemical Pharmacology·J H SchellensD D Breimer
Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D T MolowaP S Guzelian
Oct 1, 1987·The Journal of Clinical Investigation·P B WatkinsP S Guzelian
Dec 30, 1994·Biochemical and Biophysical Research Communications·Y JounaïdiM J Vilarem
Oct 1, 1994·Pharmacogenetics·J C KolarsP B Watkins
Dec 15, 1995·Toxicology·A P LiA Rasmussen
Oct 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·G R Wilkinson
Jan 1, 1997·Advances in Pharmacology·F P Guengerich
May 23, 1998·Annual Review of Pharmacology and Toxicology·K E Thummel, G R Wilkinson
Aug 27, 1998·Journal of the National Cancer Institute·T R RebbeckS B Malkowicz
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·G BertilssonA Berkenstam
Oct 24, 1998·Genes & Development·B BlumbergR M Evans
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·C A FelixT R Rebbeck
Apr 17, 1999·British Journal of Cancer·G I MurrayW T Melvin
May 21, 1999·Biochemical and Biophysical Research Communications·A WestlindM Ingelman-Sundberg
Jul 2, 1999·Virchows Archiv : an International Journal of Pathology·T YokoseK Mukai
Sep 24, 1999·Journal of the National Cancer Institute·Y AndoH Saito
Sep 24, 1999·Journal of the National Cancer Institute·B AmirimaniT R Rebbeck
Oct 8, 1999·Clinical Pharmacology and Therapeutics·M T KinironsG R Wilkinson

❮ Previous
Next ❯

Citations

Apr 22, 2008·Molecular Diagnosis & Therapy·Yongfang LiSiamak Davani
Jul 26, 2005·Journal of Human Genetics·Barkur S Shastry
Apr 15, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ehab S El DesokyJean-Pascal Siest
Jul 18, 2008·Transplantation Reviews·Hylke de Jonge, Dirk R J Kuypers
Feb 8, 2006·The Pharmacogenomics Journal·S Rodríguez-NóvoaV Soriano
Jul 26, 2005·Pharmacogenetics and Genomics·Sarah C SimMagnus Ingelman-Sundberg
Dec 14, 2005·Pharmacogenetics and Genomics·Markus SchirmerL Wojnowski
May 21, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Patrick J RobertsRoy L Hawke
Feb 8, 2008·Blood·Richard A LarsonUNKNOWN IRIS (International Randomized Interferon vs STI571) Study Group
Feb 22, 2011·Pharmacogenomics·Markus R Meyer, Hans H Maurer
Jun 23, 2011·Pharmacogenomics·Gerd MikusJohanna Weiss
Mar 1, 2006·Future Cardiology·J W van WerkumJ M Ten Berg
Jun 4, 2008·Pharmacogenomics·Dennis A HesselinkTeun van Gelder
Jul 19, 2013·Journal of Human Hypertension·Y-P ZhangH Yuan
Apr 1, 2010·European Journal of Clinical Pharmacology·Rogier R PressHenk-Jan Guchelaar
Feb 3, 2007·Expert Opinion on Drug Metabolism & Toxicology·Mary F Paine, Nicholas H Oberlies
Jun 19, 2014·Expert Opinion on Drug Metabolism & Toxicology·Pablo BarreiroVincent Soriano
Feb 23, 2010·Transplantation Proceedings·J LarribaM A Redal
Nov 26, 2008·Clinics in Laboratory Medicine·Gilbert J Burckart
Aug 19, 2008·Current Opinion in Immunology·Diana M GirnitaAdriana Zeevi
Aug 30, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Maria Alice V WillrichRosario D C Hirata
Jun 22, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jing DuLin He
May 8, 2007·International Journal of Pharmaceutics·Ebba BergmanHans Lennernäs
Jun 6, 2008·Journal of Clinical Pharmacology·J Andrew WilliamsSteven A Wrighton
Mar 30, 2010·International Journal of Andrology·W KristiansenE L Aschim
Jun 15, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Vanessa ZancanellaMauro Dacasto
Dec 13, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·S C KoehlerV W Armstrong
Aug 6, 2014·Journal of Zhejiang University. Science. B·Yu-hong LiJin-guang Ruan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.